Everyone in oncology BD is watching the ADC space this week, but most of the watching is backward-looking. The deals have already been done. The targets have already been claimed.
This edition is about what comes after that.
7 min read
Therapeutic
Therapeutic Thursday: The ADC Gold Rush Has a Crowding Problem
The clinical logic is sound, the deal volume is real, and the differentiation question is getting harder to ignore.
